Currently, biomarkers such as ER, Progesterone Receptor (PgR) and the Human Epidermal growth factor-like Receptor 2 (HER2) expression level, as well as proliferation status as measured by Ki-67, roughly distinguish patients according to breast cancer subtypes and help inform treatment choice [3,4]. This evidence concerns the gene PGR and breast carcinoma.